Goldman Sachs’s Agios Pharmaceuticals AGIO Stock Holding History

Goldman Sachs’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$403K	Buy	+11,900	New	+$337K	﹤0.01%	5735
2021 Q4	–	Sell	-27,000	Closed	-$1.25M	–	6439
2021 Q3	$1.25M	Sell	27,000 -38,300	-59%	-$1.85M	﹤0.01%	4580
2021 Q2	$3.6M	Buy	65,300 +27,000	+70%	+$1.51M	﹤0.01%	3653
2021 Q1	$1.98M	Buy	38,300 +13,300	+53%	+$659K	﹤0.01%	3997
2020 Q4	$1.08M	Buy	+25,000	New	+$988K	﹤0.01%	4145
2020 Q2	–	Sell	-100,000	Closed	-$3.55M	–	5170
2020 Q1	$3.55M	Buy	100,000 +93,400	+1,415%	+$4.32M	﹤0.01%	2905
2019 Q4	$315K	Buy	+6,600	New	+$249K	﹤0.01%	4719
2016 Q1	–	Sell	-90,000	Closed	-$5.84M	–	7057
2015 Q4	$5.84M	Buy	+90,000	New	+$5.9M	﹤0.01%	2685

Other funds holding AGIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Goldman Sachs's AGIO Position: Q1 2026 in Review

Goldman Sachs reduced its Agios Pharmaceuticals (AGIO) stake by 22% in Q1 2026, selling an estimated $6.47M and leaving 805,776 shares worth $27.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2145.

Goldman Sachs first reported a position in AGIO in Q4 2013 and has held it in 49 quarters since. The position peaked at $110M in Q1 2019. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

Goldman Sachs held 805,776 shares of Agios Pharmaceuticals worth $27.3M as of Q1 2026.
Goldman Sachs sold 228,198 Agios Pharmaceuticals shares in Q1 2026, an estimated $6.47M.
Agios Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2145 holding.
Goldman Sachs first reported a position in Agios Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
Goldman Sachs's Agios Pharmaceuticals position peaked at $110M in Q1 2019.
233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.